As reported on Business Wire, TearSolutions, a clinical-stage biotechnology company focused on ophthalmic therapies, has announced key regulatory and clinical progress for its investigational drug Lacripep® in the treatment of…
According to a story from prnewswire.com, the biopharmaceutical company Dompé recently announced that the company has received the 2019 Industry Innovation Award from the National Organization of Rare Disorders (NORD).…
The US FDA has approved the first drug to treat neurotrophic keratitis, a degenerative condition that affects the eyes. Approval of the drug, called Oxervate (cenegermin), is granted to…
According to a story from BioSpace, the US Food and Drug Administration (FDA) recently approved the drug Oxervate (cenegermin). This treatment is the first FDA approved therapy for the rare…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
